 |
Analysis of the security of rituximab together with a tumor necrosis issue inhibitor and methotrexate in patients with lively rheumatoid arthritis: outcomes from a randomized managed trial. 33.Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural harm over 2 years in patients with rheumatoid arthritis handled with rituximab together with methotrexate. 34.Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP, RESET Investigators Security and effectiveness of rituximab in patients with rheumatoid arthritis following an insufficient response to 1 prior tumor necrosis issue inhibitor: the RESET Trial. 35.Gomez-Reino JJ, Maneiro JR, Ruiz J, Rosell� R, Sanmarti R, Romero AB, MIRAR Research Group Comparative effectiveness of switching to various tumour necrosis issue (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed earlier TNF antagonists: the MIRAR Research. 36.Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint injury with rituximab plus methotrexate in early energetic rheumatoid arthritis: 2-yr outcomes from the randomised managed trial Picture.
Have a look at my page; rituximab kosten (professional (https://www.facebook.com/rituximabprecio/)) |